These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17053411)

  • 1. Perspectives on dyslipidemia and coronary heart disease in women: an update.
    Bittner V
    Curr Opin Cardiol; 2006 Nov; 21(6):602-7. PubMed ID: 17053411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia and lipid-lowering therapy in the elderly.
    Deedwania P; Volkova N
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):453-63. PubMed ID: 15889973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
    Petrella RJ; Merikle E; Jones J
    Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study.
    Ye X; Gross CR; Schommer J; Cline R; St Peter WL
    Clin Ther; 2007 Dec; 29(12):2748-57. PubMed ID: 18201593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on dyslipidemia and coronary heart disease in women.
    Bittner V
    J Am Coll Cardiol; 2005 Nov; 46(9):1628-35. PubMed ID: 16256860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2008 May; 28(5):562-9. PubMed ID: 18447654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current questions regarding the use of statins in patients with coronary heart disease.
    Rallidis LS; Lekakis J; Kremastinos DT
    Int J Cardiol; 2007 Nov; 122(3):188-94. PubMed ID: 17399827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive lipid-lowering therapy in patients with coronary heart disease.
    Lauderdale SA; Sheehan AH
    Ann Pharmacother; 2005 Feb; 39(2):329-34. PubMed ID: 15613464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient expectations on lipid-lowering drugs.
    Lytsy P; Westerling R
    Patient Educ Couns; 2007 Jul; 67(1-2):143-50. PubMed ID: 17433602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.